Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes Care|August 27, 2005
The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic studyTim Heise, Susanne Bott, Corinna Tusek, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Diabetes Technology & Therapeutics|March 18, 2025
Evaluating the Adequacy of Coefficient of Variation and Standard Deviation as Metrics of Glucose Variability in Type 1 Diabetes Based on Data from the GOLD and SILVER TrialsPavel Fatulla, Henrik Imberg, Sofia Sterner Isaksson, et al.
Diabetes Care|December 24, 2017
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon AnalogUlrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, et al.
Journal of Diabetes Science and Technology|April 16, 2016
Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study)Marcus Lind, William Polonsky, Irl B Hirsch, et al.
The Journal of Clinical Investigation|January 28, 2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsEle Ferrannini, Elza Muscelli, Silvia Frascerra, et al.
Angiology|December 31, 2020
Improving the Assessment of Flow-Mediated Dilation Through Detection of Peak Time in Healthy Subjects and Subjects With Type 2 DiabetesTheresa Herbrand, Hans-Veit Coester, Roberto Sansone, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kineticsDavid Polidori, Sue Sha, Tim Heise, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes Care|August 27, 2005
The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic studyTim Heise, Susanne Bott, Corinna Tusek, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Diabetes Technology & Therapeutics|March 18, 2025
Evaluating the Adequacy of Coefficient of Variation and Standard Deviation as Metrics of Glucose Variability in Type 1 Diabetes Based on Data from the GOLD and SILVER TrialsPavel Fatulla, Henrik Imberg, Sofia Sterner Isaksson, et al.
Diabetes Care|December 24, 2017
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon AnalogUlrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, et al.
Journal of Diabetes Science and Technology|April 16, 2016
Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study)Marcus Lind, William Polonsky, Irl B Hirsch, et al.
The Journal of Clinical Investigation|January 28, 2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsEle Ferrannini, Elza Muscelli, Silvia Frascerra, et al.
Angiology|December 31, 2020
Improving the Assessment of Flow-Mediated Dilation Through Detection of Peak Time in Healthy Subjects and Subjects With Type 2 DiabetesTheresa Herbrand, Hans-Veit Coester, Roberto Sansone, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kineticsDavid Polidori, Sue Sha, Tim Heise, et al.
Pageof 15